Reuters, Chicago, reported that the new anti-cancer drug PLX4032, being developed by Plexxicon Pharmaceuticals, has performed well in early clinical trials for the treatment of melanoma. In 32 patients with advanced melanoma, 81% of the patients had some tumor shrinkage.
During this period, the researchers performed biopsies on the patients before and two weeks after they were administered. The results showed that the drugs can act directly on the tumor cells and can almost completely block a chemical pathway in the cancer cells. The tumor shrinks.
Plexxicon will further observe how the drugs change the molecular structure of tumor cells and clarify the mechanism of action of the drugs. This can predict the prospect of drug development in advance and avoid discovering drug development failure after conducting high-cost large-scale clinical trials.
Currently, Plexxico is working with Roche to develop a diagnostic method that can identify patients with BRAF mutations because these patients are more likely to benefit from the drug.
During this period, the researchers performed biopsies on the patients before and two weeks after they were administered. The results showed that the drugs can act directly on the tumor cells and can almost completely block a chemical pathway in the cancer cells. The tumor shrinks.
Plexxicon will further observe how the drugs change the molecular structure of tumor cells and clarify the mechanism of action of the drugs. This can predict the prospect of drug development in advance and avoid discovering drug development failure after conducting high-cost large-scale clinical trials.
Currently, Plexxico is working with Roche to develop a diagnostic method that can identify patients with BRAF mutations because these patients are more likely to benefit from the drug.
Sodium Erythorbate Fcc Grade,Sodium Erythorbate Powder,Sodium Erythorbate Food Additive,Food Grade Sodium Erythorbate
SHANDONG BAISHENG BIOTECHNOLOGY COM , https://www.baishengbioproducts.com